Sinfonia Biotherapeutics: € 50k

Sinfonia Biotherapeutics is developing targeted therapies for genetically defined CNS orphan indications that are built on a proprietary medical device – the Brain Repair Device – that overcome several of the existing challenges associated with the failing clinical development of drug candidates for neurodegenerative diseases today. Sinfonia Biotherapeutics was granted € 50k from the SME Instrument HORIZON 2020, phase 1. GAEU’s team at Horizon 2020 Centre of Excellence wrote the proposal.

MORE REFERENCES

FOLLOW US